Tag: GlobalData
Trump’s NIH funding cuts & freezes raise concerns over US biotech...
According to GlobalData’s Pharma Intelligence Center Grants Database, SBIR and STTR grants involving innovator drugs saw a 37% increase in total grant value from $237 million in 2020 to $326 million in 2024
Amgen strategic hiring push in India: GlobalData insights on R&D growth...
The company is focused on developing and implementing innovative strategies for indirect materials procurement, overseeing data analytics governance, and to improve procurement processes
Lilly’s GBP279 million investment set to boost UK life sciences sector
As per GlobalData, the initiative is set to accelerate early-stage ventures and spearhead advancements in obesity treatments, invigorating the UK life sciences sector
Biologic therapies mark progress in severe asthma treatment & remission potential:...
While biologics have shown great promise, barriers such as cost, access, and insurance coverage limit their availability, particularly in underserved communities
Food waste crisis accelerates sustainable practices across APAC food & beverage...
Governments across Asia have launched various initiatives to act against the crisis
Top 20 global biopharma players witness 2% growth in market capitalization...
Industry leaders are driving innovation by advancing their R&D pipelines and entering billion-dollar strategic alliances
Epigenetic drugs witness 375% growth in series A venture financing in...
GlobalData’s Pharma Intelligence Center Deals Database reveals that companies developing epigenetic drugs received over $1 billion in total series A venture financing from 2019 to 2024YTD
China’s surge in antibody-drug conjugates positions it as key oncology market,...
ADCs have become a focal point in oncology due to their ability to selectively target cancer cells, resulting in reduced off-target side effects.
GLP1R innovator drugs drive over $6.2 billion in licensing agreement deals...
Biopharmaceutical companies are now focusing on advancing these drugs to enhance efficacy and expand their therapeutic scope beyond type 2 diabetes and obesity
US respiratory test market faces volatility ahead of flu season: GlobalData
Transition to complex, expensive multi-target tests contributes to market unpredictability and significant variations in sales and revenue